Immunize
Nirsevimab
search
Nirsevimab
, Nirsevimab-alip, Beyfortus
See Also
RSV Vaccine
Palivizumab
Indications
RSV Prophylaxis in all children age <8 months in their first RSV season (typically October to March in U.S.)
Not needed if mother received
RSV Vaccine
at least 2 weeks prior to delivery (during RSV season)
High risk infants (e.g.
Congenital Heart Disease
) should receive Nirsevimab regardless of maternal
RSV Vaccine
RSV Prophylaxis in all children age 8 to 19 months in their second RSV season who are at risk for severe disease
Single dose alternative to
Palivizumab
See
Palivizumab
for high risk indications
High risk infants may be given Nirsevimab and stop
Palivizumab
if less than 5 doses of
Palivizumab
given
Mechanism
Nirsevimab is a
Monoclonal Antibody
Dosing
Background
Nirsevimab is given as a single
IM Injection
per season ($500/dose in 2023)
Contrast with
Palivizumab
which is dosed monthly ($1800/dose in 2023)
Give dose shortly before RSV season (or in the first week of life if born during RSV season)
Season 1
Weight <5 kg: 50 mg IM once per season
Weight >5 kg: 100 mg IM once per season
Season 2
Give 200 mg IM (split into two 100 mg doses at different injection sites) once per season
Efficacy
Prevents RSV hospitalization in normal risk infants for up to 5 months after injection (NNT 48)
Similar efficacy in high risk infants as for
Palivizumab
(
Synagis
)
Adverse Effects
Hypersensitvity reaction
References
(2023) Presc Lett 30(10): 55-6
Type your search phrase here